Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sunshine Biopharma Inc. (OTC: SBFM).

Full DD Report for SBFM

You must become a subscriber to view this report.


Recent News from (OTC: SBFM)

Sunshine Biopharma Announces Extension of The Term of Its Brokered Up To $10 Million Private Placement Financing
MONTREAL, QB / ACCESSWIRE / May 10, 2018 / Sunshine Biopharma, Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of cancer and other acute and chronic indications, today announced that it has signed an agree...
Source: ACCESSWIRE
Date: May, 10 2018 09:25
Sunshine Biopharma Completes the Acquisition of Atlas Pharma
MONTREAL, QB / ACCESSWIRE / January 4, 2018 / On January 1, 2018, Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of various forms of cancer, completed the acquisition of Atlas Pharma In...
Source: ACCESSWIRE
Date: January, 04 2018 13:25
Sunshine Biopharma Announces the Terms of Its Brokered up to $10 Million in Private Placement Financing
MONTREAL, QC / ACCESSWIRE / September 19, 2017 / Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed negotiations of the ter...
Source: ACCESSWIRE
Date: September, 19 2017 09:20
Sunshine Biopharma Enters into an Investment Banking Agreement with Jitney Trade to Raise up to $10 Million for Clinical Trials of Adva-27a Anticancer Drug
MONTREAL, QC / ACCESSWIRE / September 5, 2017 / Sunshine Biopharma Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development, and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an investment banking agr...
Source: ACCESSWIRE
Date: September, 05 2017 16:24
Sunshine Biopharma Releases Results of Independent Valuation
MONTREAL, QC / ACCESSWIRE / June 26, 2017 / Sunshine Biopharma Inc. (OTC PINK: SBFM) is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead anticancer compound, Adva-27a, has proven effe...
Source: ACCESSWIRE IA
Date: June, 26 2017 09:00
Sunshine Biopharma Files an Application with Health Canada for a Drug Establishment License
MONTREAL, QC / ACCESSWIRE / June 19, 2017 / Sunshine Biopharma Inc. (OTC PINK: SBFM), a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications, is pleased to announce that it has filed an application...
Source: ACCESSWIRE IA
Date: June, 19 2017 09:26
Sunshine Biopharma Currently Reviewing Twenty-Three Additional Generic Products for In-Licensing
MONTREAL, QC / ACCESSWIRE / January 11, 2017 / Sunshine Biopharma Inc. (OTC PINK: SBFM), a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications, is pleased to announce that it currently has twenty-t...
Source: ACCESSWIRE IA
Date: January, 11 2017 09:25
Sunshine Biopharma Signs Strategic Alliance Agreement with Atlas Pharma
MONTREAL, QC / ACCESSWIRE / December 9, 2016 / Sunshine Biopharma Inc. (OTC PINK: SBFM), a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications, is pleased to announce that it has signed a Strategic...
Source: ACCESSWIRE IA
Date: December, 09 2016 09:20
Sunshine Biopharma Signs Licensing Agreement for Three Additional Generic Products for Treatment of Cancer and BPH
MONTREAL, QC--(Marketwired - Jun 30, 2016) - Sunshine Biopharma Inc. ( OTCQB : SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to announce that it has signed a Cross Referencing Agr...
Source: Marketwired
Date: June, 30 2016 09:15
Sunshine Biopharma Signs Licensing Agreement for Anastrozole, the Company's First Generic Drug for Treatment of Breast Cancer
MONTREAL, QC--(Marketwired - May 11, 2016) - Sunshine Biopharma Inc. ( OTCQB : SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, is pleased to announce that it has signed a Cross Referencing Agr...
Source: Marketwired
Date: May, 11 2016 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-140.00170.00150.00170.00151,960,084
2018-08-130.0020.00170.0020.00177,963,894
2018-08-100.00180.0020.0020.001611,740,467
2018-08-090.0020.00180.0020.001611,098,671
2018-08-080.00190.0020.00230.00199,034,575

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-102,405,00011,737,46720.4899Cover
2018-08-091,502,5547,204,59620.8555Cover
2018-08-081,491,3258,699,57517.1425Cover
2018-08-076,468,71321,788,54429.6886Cover
2018-08-06530,022680,02277.9419Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SBFM.


About Sunshine Biopharma Inc. (OTC: SBFM)

Logo for Sunshine Biopharma Inc. (OTC: SBFM)

Sunshine Biopharma is a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.

 

 

 

Current Management

  • Dr. Steve N. Slilaty / CEO
  • Abderrazzak Merzouki / COO
  • Camille Sebaaly / CFO
  • Dr. Steve N. Slilaty / Chairman
  • Abderrazzak Merzouki /
  • Camille Sebaaly /

Current Share Structure

  • Market Cap: $8,526,536 - 03/09/2018
  • Authorized: 3,000,000,000 - 03/09/2018
  • Issue and Outstanding: 945,292,259 - 03/09/2018
  • Float: 302,139,425 - 08/16/2017

 


Recent Filings from (OTC: SBFM)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 04 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 15 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 13 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 05 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 11 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 23 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 12 2017
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2017

 

 


Daily Technical Chart for (OTC: SBFM)

Daily Technical Chart for (OTC: SBFM)


Stay tuned for daily updates and more on (OTC: SBFM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SBFM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SBFM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SBFM and does not buy, sell, or trade any shares of SBFM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/